T-cell engager market size for multiple myeloma
Total market value of T-cell engagers for multiple myeloma.
Unit billion USD Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
T-cell engager market size for multiple myeloma
United States, 2032
Every record
All records
1 record · 1 region · 2032
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences | GSK | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). T-cell engager market size for multiple myeloma. Retrieved from https://statorigin.org/indicators/t-cell-engager-market-size-for-multiple-myeloma